Two-thirds of Americans want an independent body to oversee prescription drug pricing. » Read More
By: Melissa Lee
Intra-Cellular Therapies shares plunge 68 percent after study results on a schizophrenia drug trial. CNBC's Seema Mody reports. » Read More
Mylan CEO Heather Bresch's testifies the rising price of the EpiPen on Capitol Hill and discusses EpiPen profits and program costs.
Mylan CEO Heather Bresch testifies about the EpiPen price hike on Capitol Hill.
Mylan also faces heat from multiple regulatory and legal agencies over huge cost increases for the anti-allergy auto-injectors.
Bill George, Harvard Business School Senior Fellow and Former Medtronic Chairman, weighs in on Mylan CEO Heather Bresch's upcoming testimony on Capitol Hill over the EpiPen pricing debate.
A drugmaker producing acne creams has raised the price of two of its treatments to almost $10K a tube, the Financial Times reports.
Mylan CEO Heather Bresch is set to testify Wednesday before a House committee over sky-high price hikes for lifesaving EpiPens.
Mylan CEO's mother Gayle Manchin used education position to encourage purchase of EpiPen, according to USA Today.
Tobira Therapeutics shares surge after Allergan agrees to buy the drug developer for $1.7. CNBC's Meg Tirrell reports the details, as well as other biotech takeover targets surrounding progressive liver disease "NASH."
Less than 10 percent of authorized doctors prescribe the medication buprenorphine to more than 75 patients.
CNBC's Meg Tirrell reports on the premium Allergan is paying with its purchase of Tobira Therapeutics.
Shares of Sarepta Therapeutics jumped more than 13 percent in Tuesday trade after closing higher Monday on government approval of its drug.
Tobira shares rise after Allergen announces to buy Tobira Therapeutics in a deal worth up to $1.7 billion.
GlaxoSmithKline said it had chosen its head of consumer health care, Emma Walmsley, as its new CEO, after considering other candidates.
"Fast Money" trader Dan Nathan discusses unusual options activity in the biotech sector.
Ed Kaye, Sarepta Therapeutics interim CEO, speaks to CNBC's Meg Tirrell about what's next for the company following FDA's recent approval of muscular dystrophy drug eteplirsen.
Moncef Slaoui, GlaxoSmithKline chairman of vaccines, discusses preparing for a pandemic and what GSK is doing to tackle global health threats.
Get the best of CNBC in your inbox